Neurocrine Biosciences combines a perfect Piotroski F-Score of 9 out of 9, a wide economic moat, and 42% revenue growth at a PEG of 0.45 and forward P/E of 12.5x — making it one of the higher-conviction quality-growth combinations in the specialty pharmaceutical sector — though heavy revenue concentration in a single product line and current negative price momentum create real near-term risk.
Thesis pillars
- Revenue Growth At Value Peg→Stable
- Wide Moat High Quality Compounder→Stable
- Earnings Beat Track Record→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 11, 2026
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $142.56. Recent C-suite change — blocks BUY_NOW at $145.53. Engine's entry $142.56 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk).
Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders, with INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea and CRENESSITY (crinecerfont) for classic congenital adrenal... Read more
Wait for pullback to $142.56. Recent C-suite change — blocks BUY_NOW at $145.53. Engine's entry $142.56 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk). Chart setup: Death cross but MACD improving, RSI 59. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.30, quality 8.3/10, growth 9.1/10). Score 7.3/10, high confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, positive momentum, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: moderate.
About Neurocrine Biosciences, Inc.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences reported $2.51 billion in INGREZZA (valbenazine) net product sales for 2025 and $301.2 million in CRENESSITY (crinecerfont) net product sales during its first full year post-December 2024 FDA approval, making the San Diego-based biopharmaceutical company two-product commercial. INGREZZA — the first FDA-approved treatment for tardive dyskinesia, approved May 2017, and also approved for Huntington's disease chorea in August 2023 — remains the primary revenue driver.
Neurocrine Biosciences earns revenue through U.S. prescription sales of INGREZZA distributed through a limited specialty network of select specialty pharmacy providers, wholesale distributors, and specialty distributors; CRENESSITY is sold exclusively through a single specialty pharmacy provider, consistent with its rare disease focus. A specialized sales force of approximately 600 professionals targets neurology, psychiatry, long-term care, and rare disease prescribers. Manufacturing is fully outsourced to third-party CMOs and API suppliers, with multiple manufacturers and long-term commercial supply agreements in place to support continued production. Royalties and collaboration revenues from elagolix (for endometriosis and uterine fibroids) flow through the collaboration with AbbVie, which retains global commercialization rights. INGREZZA faces competition from AUSTEDO (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, while CRENESSITY competes primarily with high-dose corticosteroid monotherapy as the existing standard of care for CAH.
Show full overview
INGREZZA's commercial longevity is anchored by 22 FDA Orange Book-listed U.S. patents expiring between 2027 and 2040, with the core active pharmaceutical ingredient patent (U.S. Patent No. 8,039,627) extended to 2031 via patent term extension. Settlement agreements reached in 2023 with all ANDA filers grant generic entrants the right to launch generic valbenazine beginning March 1, 2038, or earlier under certain circumstances — establishing a defined exclusivity window. Pipeline programs osavampator (Phase 3 in MDD, initial topline data expected 2027) and direclidine (Phase 3 in schizophrenia, initial data also expected 2027) are intended to diversify the revenue base ahead of the 2038 generic entry date, though both face binary readout risk.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Neurocrine Biosciences, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Neurocrine Biosciences, Inc.
Latest news
- NEWS Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return - Simply Wall Street — Simply Wall Street positive
- NEWS Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance — Yahoo Finance neutral
- NEWS AMG National Trust Bank Acquires Shares of 12,326 Neurocrine Biosciences, Inc. $NBIX - MarketBeat — MarketBeat neutral
- NEWS Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - qz.com — qz.com neutral
- NEWS Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why - qz.com — qz.com positive
Generated 2026-10-29T13:34:03Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductINGREZZA10-K Item 1: 'INGREZZA net product sales were $2.51 billion for 2025... and accounted for a significant portion of our total net product sales during each of these years'
- MEDIUMCustomerconcentrated customers10-K Item 1A: 'Our customers are concentrated and therefore the loss of a significant customer may harm our business'
- LOWcounterpartysingle specialty pharmacy provider10-K Item 1: 'we sell CRENESSITY in the U.S. through a single specialty pharmacy provider'
Material Events(8-K, last 90d)
- 2026-05-28Item 5.02LOWShareholders approved amendment of 2025 Equity Incentive Plan at May 27, 2026 Annual Meeting. Three Class III directors elected for terms expiring 2029. Ernst & Young LLP ratified as auditor for FY2026. No executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $142.56. Recent C-suite change — blocks BUY_NOW at $145.53. Engine's entry $142.56 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk). Chart setup: Death cross but MACD improving, RSI 59. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.30, quality 8.3/10, growth 9.1/10). Target $185.60 (+27.5%), stop $135.80 (−7.2%), A.R:R 3.0:1. Score 7.3/10, high confidence.
Take-profit target: $185.60 (+27.5% upside). Target $185.60 (+27.5%), stop $135.80 (−7.2%), A.R:R 3.0:1. Stop-loss: $135.80.
Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk); Below 200-MA (29d, -1.2%).
Neurocrine Biosciences, Inc. trades at a P/E of 21.3 (forward 12.2). TrendMatrix value score: 7.7/10. Verdict: Buy (Wait for Entry).
37 analysts cover NBIX with a consensus score of 4.3/5. Average price target: $206.
What does Neurocrine Biosciences, Inc. do?Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and...
Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders, with INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia as its two FDA-approved commercial products. INGREZZA generated $2.51 billion in net product sales in 2025; CRENESSITY generated $301.2 million in its first full year following December 2024 FDA approval.